Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Long-term pharmacological therapy of Brugada syndrome: is J-wave attenuation a marker of drug efficacy?

Hasegawa K, Ashihara T, Kimura H, Jo H, Itoh H, Yamamoto T, Aizawa Y, Horie M.

Intern Med. 2014;53(14):1523-6.

2.

J wave elevation to monitor quinidine efficacy in early repolarization syndrome.

Sacher F, Derval N, Horlitz M, Haïssaguerre M.

J Electrocardiol. 2014 Mar-Apr;47(2):223-5. doi: 10.1016/j.jelectrocard.2013.10.008.

PMID:
24332747
3.

Variable electrocardiographic effects of short-term quinidine sulfate administration in Brugada syndrome.

Watanabe H, Chinushi M, Washizuka T, Sugiura H, Hirono T, Komura S, Hosaka Y, Yamaura M, Tanabe Y, Furushima H, Fujita S, Aizawa Y.

Pacing Clin Electrophysiol. 2005 May;28(5):372-7.

PMID:
15869667
4.

[Doubts of the cardiologist regarding an electrocardiogram presenting QRS V1-V2 complexes with positive terminal wave and ST segment elevation. Consensus Conference promoted by the Italian Cardiology Society].

Oreto G, Corrado D, Delise P, Fedele F, Gaita F, Gentile F, Giustetto C, Michelucci A, Padeletti L, Priori S.

G Ital Cardiol (Rome). 2010 Nov;11(11 Suppl 2):3S-22S. Italian.

PMID:
21361048
5.

Transition of the ST segment from a J wave to a coved-type elevation before ventricular fibrillation induced by coronary vasospasm in the precordial leads.

Inoue M, Matsubara T, Yasuda T, Miwa K, Kanaya H.

J Electrocardiol. 2010 Sep-Oct;43(5):418-21. doi: 10.1016/j.jelectrocard.2010.06.006.

PMID:
20667548
6.
7.

Mechanisms underlying the development of the electrocardiographic and arrhythmic manifestations of early repolarization syndrome.

Koncz I, Gurabi Z, Patocskai B, Panama BK, Szél T, Hu D, Barajas-Martínez H, Antzelevitch C.

J Mol Cell Cardiol. 2014 Mar;68:20-8. doi: 10.1016/j.yjmcc.2013.12.012.

8.

J wave syndromes: molecular and cellular mechanisms.

Antzelevitch C.

J Electrocardiol. 2013 Nov-Dec;46(6):510-8. doi: 10.1016/j.jelectrocard.2013.08.006. Review.

9.

Cellular mechanisms underlying the effects of milrinone and cilostazol to suppress arrhythmogenesis associated with Brugada syndrome.

Szél T, Koncz I, Antzelevitch C.

Heart Rhythm. 2013 Nov;10(11):1720-7. doi: 10.1016/j.hrthm.2013.07.047.

10.

Cellular mechanism underlying hypothermia-induced ventricular tachycardia/ventricular fibrillation in the setting of early repolarization and the protective effect of quinidine, cilostazol, and milrinone.

Gurabi Z, Koncz I, Patocskai B, Nesterenko VV, Antzelevitch C.

Circ Arrhythm Electrophysiol. 2014 Feb;7(1):134-42. doi: 10.1161/CIRCEP.113.000919.

11.

Combination therapy of cilostazol and bepridil suppresses recurrent ventricular fibrillation related to J-wave syndromes.

Shinohara T, Ebata Y, Ayabe R, Fukui A, Okada N, Yufu K, Nakagawa M, Takahashi N.

Heart Rhythm. 2014 Aug;11(8):1441-5. doi: 10.1016/j.hrthm.2014.05.001.

PMID:
24813378
12.

Conversion of Brugada type I to type III and successful control of recurrent ventricular arrhythmia with cilostazol.

Ağaç MT, Erkan H, Korkmaz L.

Arch Cardiovasc Dis. 2014 Aug-Sep;107(8-9):476-8. doi: 10.1016/j.acvd.2012.06.008. No abstract available.

13.

Electrical storm in patients with brugada syndrome is associated with early repolarization.

Kaneko Y, Horie M, Niwano S, Kusano KF, Takatsuki S, Kurita T, Mitsuhashi T, Nakajima T, Irie T, Hasegawa K, Noda T, Kamakura S, Aizawa Y, Yasuoka R, Torigoe K, Suzuki H, Ohe T, Shimizu A, Fukuda K, Kurabayashi M, Aizawa Y.

Circ Arrhythm Electrophysiol. 2014 Dec;7(6):1122-8. doi: 10.1161/CIRCEP.114.001806.

14.
15.

Effects of quinidine on the action potential duration restitution property in the right ventricular outflow tract in patients with brugada syndrome.

Ashino S, Watanabe I, Kofune M, Nagashima K, Ohkubo K, Okumura Y, Mano H, Nakai T, Kunimoto S, Kasamaki Y, Hirayama A.

Circ J. 2011;75(9):2080-6.

16.

Brugada syndrome in children.

Crosson JE, Nies M.

Expert Rev Cardiovasc Ther. 2015 Feb;13(2):173-81. doi: 10.1586/14779072.2015.999765. Review.

PMID:
25583159
17.
18.

Quinidine induced electrocardiographic normalization in two patients with Brugada syndrome.

Alings M, Dekker L, Sadée A, Wilde A.

Pacing Clin Electrophysiol. 2001 Sep;24(9 Pt 1):1420-2.

PMID:
11584468
19.

Is a drug-challenge test with propafenone adequate to exclude Brugada syndrome?

Yildiz BS, Gungor H, Gul I, Bilgin M, Zoghi M, Akilli A.

Cardiovasc J Afr. 2013 Mar 23;24(2):e4-6. doi: 10.5830/CVJA-2012-068.

20.

ST segment elevation in the right precordial leads induced with class IC antiarrhythmic drugs: insight into the mechanism of Brugada syndrome.

Fujiki A, Usui M, Nagasawa H, Mizumaki K, Hayashi H, Inoue H.

J Cardiovasc Electrophysiol. 1999 Feb;10(2):214-8.

PMID:
10090224
Items per page

Supplemental Content

Support Center